Analyst Research

Report Title Price
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Oculus Innovative Sciences Inc Receives FDA Clearance for Microcyn Scar Management HydroGel


Wednesday, 4 Dec 2013 08:08am EST 

Oculus Innovative Sciences Inc:Says that it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the company's new Microcyn Scar Management HydroGel.Says The Rx product, under the supervision of a healthcare professional, is intended for the management of old and new hypertrophic and keloid scarring resulting from burns, general surgical procedures and trauma wounds.Says Oculus U.S. dermatology partner, Quinnova Pharmaceuticals, intends to commercialize the product in the first half of 2014. 

Company Quote